Join our daily newsletter At The Bell to receive exclusive market insights
Recce Ltd (ASX:RCE) has released news that its flagship antibacertial and anti-infective drug, R327, has in a simulated model shown the drug could technically be effective as an inhalant, which would add another mechanism by which Recce can administer the drug, potentially expanding down-the-line commercial opportunities.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
Disclaimer: This content has been prepared as part of a partnership with Recce Pharma Ltd and is intended for informational purposes only.
Effective against E. Coli, UTIs, and even infections stemming from diabetes-related-amputations, R327 is shaping up as a broad-based antibacterial drug with promising applications, especially in a world where superbugs are already a reality.
To that end, the model Recce used in its Wednesday disclosure looked at the bacteria A. baumannii, a bacteria already resistant to many common antibiotics in hospital settings around the world, and one of the most commonly acquired infections while in a hospital.
In the model, Recce observed that inhaled R327 would likely decrease levels of the bacteria in the body which could drastically improve the outcomes for patients whose lungs and respiratory tracts become infected. Recce noted on Wednesday that the drug Meropenem, “a common standard-of-care antibiotic,” can’t always be converted to inhalant form, potentially outlining a commercial edge for the company.
“These results further validate the versatility of R327, administered as an inhaled formulation, as a potential treatment for serious, drug-resistant lung infections. Unlike other antibiotics used against resistant pathogens, such as meropenem, which cannot be nebulised due to solubility limitations, R327 can be effectively delivered as a fine mist directly to the lung, precisely where the infection occurs,” RCE CEO James Graham said.
“The potential to administer R327 via nebuliser or ventilator provides a significant real-world advantage in hospital settings, including intensive care and emergency environments where rapid, localised treatment is critical.”
RCE last traded at 41.5cps.
Join the discussion: See what HotCopper users are saying about Recce Pharma Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
